Tag Archives: Approves

FDA Approves Anjeso (meloxicam injection) for the Management of Moderate to Severe Pain

FDA Approves Anjeso (meloxicam injection) for the Management of Moderate to Severe Pain Print this page MALVERN, Pa., Feb. 20, 2020 (GLOBE NEWSWIRE) — Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA)… Read More »

FDA Approves Pemfexy (pemetrexed for injection) as a Branded Alternative to Alimta

FDA Approves Pemfexy (pemetrexed for injection) as a Branded Alternative to Alimta Print this page WOODCLIFF LAKE, N.J.–(BUSINESS WIRE) February 10, 2020 –Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it has received final approval from the U.S. Food and Drug Administration (“FDA”) for its novel product, Pemfexy (pemetrexed for injection),… Read More »

FDA Approves Fiasp (insulin aspart injection) for the Treatment of Children with Diabetes

Print this page PLAINSBORO, N.J., Jan. 6, 2020 /PRNewswire/ — Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved Fiasp (insulin aspart injection) 100 u/mL for use as a new mealtime insulin option for children with diabetes.1 Fiasp is the first and only fast-acting mealtime insulin injection that does not… Read More »

FDA Approves Vascepa (icosapent ethyl) to Reduce Cardiovascular Risk

Print this page DUBLIN, Ireland and BRIDGEWATER, N.J., Dec. 13, 2019 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ: AMRN) today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication and label expansion for Vascepa (icosapent ethyl) capsules. After more than a decade of development and testing, Vascepa is now the first… Read More »

FDA Approves Beovu (brolucizumab-dbll) for the Treatment of Wet Age-Related Macular Degeneration (AMD)

FDA Approves Beovu (brolucizumab-dbll) for the Treatment of Wet Age-Related Macular Degeneration (AMD) Print this page EAST HANOVER, N.J., Oct. 8, 2019 /PRNewswire/ — Novartis today announced that the U.S. Food and Drug Administration (FDA) approved Beovu (brolucizumab-dbll) injection, also known as RTH258, for the treatment of wet age-related macular degeneration (AMD)1. Beovu is the… Read More »

FDA Approves Reyvow (lasmiditan), the First Serotonin (5-HT) 1F Receptor Agonist for the Acute Treatment for Migraine

FDA Approves Reyvow (lasmiditan), the First Serotonin (5-HT) 1F Receptor Agonist for the Acute Treatment for Migraine Print this page INDIANAPOLIS, Oct. 11, 2019 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Reyvow (lasmiditan) an oral medication for the acute treatment of migraine,… Read More »